Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash & Equivalents (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Cash & Equivalents for 15 consecutive years, with $120.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 5.62% to $120.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $120.5 million through Dec 2025, down 5.62% year-over-year, with the annual reading at $120.5 million for FY2025, 5.62% down from the prior year.
  • Cash & Equivalents hit $120.5 million in Q4 2025 for Corcept Therapeutics, down from $125.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $299.9 million in Q1 2023 to a low of $35.3 million in Q2 2022.
  • Historically, Cash & Equivalents has averaged $111.8 million across 5 years, with a median of $107.3 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: tumbled 62.96% in 2022 and later surged 387.68% in 2023.
  • Year by year, Cash & Equivalents stood at $77.6 million in 2021, then dropped by 14.54% to $66.3 million in 2022, then soared by 104.36% to $135.6 million in 2023, then dropped by 5.82% to $127.7 million in 2024, then decreased by 5.62% to $120.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for CORT at $120.5 million in Q4 2025, $125.1 million in Q3 2025, and $102.7 million in Q2 2025.